The latest update is out from BerGenBio ASA ( (BRRGF) ).
BerGenBio ASA has announced promising results from a study published in Nature Communications, highlighting the effectiveness of its selective AXL inhibitor, bemcentinib, in combination with low-dose cytarabine for relapsed/refractory acute myeloid leukemia (AML) patients. The study showed an overall survival of 7.8 months for patients treated with this combination, significantly longer than the current expected survival of 2.9-4 months for this difficult-to-treat population. These findings suggest that bemcentinib could be a promising treatment option for AML patients with high unmet medical needs, potentially improving BerGenBio’s positioning in the biopharmaceutical industry.
More about BerGenBio ASA
BerGenBio ASA is a clinical-stage biopharmaceutical company based in Bergen, Norway, with a subsidiary in Oxford, UK. The company is focused on developing transformative drugs targeting AXL, a potential cornerstone of therapy for aggressive diseases, including cancer. BerGenBio is listed on the Oslo Stock Exchange under the ticker BGBIO.
YTD Price Performance: 25.00%
Technical Sentiment Signal: Buy
Current Market Cap: $6.09M
See more data about BRRGF stock on TipRanks’ Stock Analysis page.